Sara Tolaney

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  

Sara Tolaney
Dec 16, 2024, 17:51 | Insight
Best of 2024 SABCS - San Antonio Breast Cancer Symposium
The SABCS 2024 (San Antonio Breast Cancer Symposium) took place from December 10th to 13th,…
Dec 16, 2024, 04:11 | Insight
Highlights from Day 4 of SABCS 2024
The SABCS 2024 (San Antonio Breast Cancer Symposium) took place from December 10th to 13th,…
Dec 14, 2024, 17:00 | Insight
Insights on PATINA trial from SABCS 2024
Pre-clinical data showed that CDK 4/6 inhibition plays a role in HER2+ disease. Phase 2…
Dec 14, 2024, 15:44 | Blog
Sara Tolaney: First line treatment approaches in HER2+ BC
Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, shared a…
Dec 13, 2024, 22:22 | Blog
SABCS24 Day 3 Highlights from Oncology Brothers
Oncology Brothers shared a post on X: "SABCS24 Day 3 Highlights  1. EUROPA: ET vs…
Dec 13, 2024, 15:52 | Blog
SOLTI-2103 VALENTINE Trial: Phase II Trial of Neoadjuvant Patritumab Deruxtecan vs. Chemotherapy for High-Risk HR+/HER2- Early Breast Cancer
Neoadjuvant treatment for high-risk HR+/HER2- early breast cancer (EBC) remains challenging, with recurrence risks persisting…
Dec 13, 2024, 06:44 | Blog
Sara Tolaney: HER3DXd showed pCR and ORR rates similar to standard multi-agent chemotherapy
Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, shared a…
Dec 13, 2024, 05:49 | Insight
Highlights from Day 3 of SABCS 2024
The SABCS 2024 (San Antonio Breast Cancer Symposium) is taking place from December 10th to…
Dec 12, 2024, 20:45 | Blog
Sara Tolaney: Beautiful discussion of EMBER-3 by Harold Burstein
Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, shared a…
Dec 12, 2024, 16:50 | Insight
Imlunestrant and Abemaciclib: A Study in Advanced Breast Cancer
Imlunestrant has been approved for the treatment of breast cancer. It is a next-generation, brain-penetrant,…
Dec 12, 2024, 15:40 | Blog
Sara Tolaney: DESTINY-Breast06 - Efficacy by pace of disease progression
Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, shared a…
Dec 12, 2024, 13:26 | Insight
Highlights from Day 2 of SABCS 2024
The SABCS 2024 (San Antonio Breast Cancer Symposium) is taking place from December 10th to…
Dec 12, 2024, 08:04 | Insight
Highlights from Day 1 of SABCS 2024 by Sara Tolaney
The SABCS 2024 (San Antonio Breast Cancer Symposium) is taking place from December 10th to…
Dec 11, 2024, 19:12 | Insight
Highlights from Day 1 of SABCS 2024
The SABCS 2024 (San Antonio Breast Cancer Symposium) is taking place from December 10th to…
Dec 11, 2024, 17:38 | Blog
SABCS24 Day 1 Highlights by Oncology Brothers
Oncology Brothers shared a post on X: "SABCS24 Day 1 Highlights CommunityOnc: FDA Oncology Reviews recent…
Dec 11, 2024, 16:46 | Blog
Sara Tolaney: Start early, it takes lots of time
Dana-Farber’s Breast Oncology Center posted on X: "Dr. Sara Tolaney offered great tips and strategies for…
Dec 8, 2024, 06:53 | Insight
The role of ADCs in the treatment of patients with Breast Cancer Brain Metastases - Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared a post on X, about a recent paper by Stacey…
Dec 4, 2024, 09:54 | Positive
100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2024
Starting on August 26, in honor of Women’s Equality Day in the United States, which…
Nov 28, 2024, 18:17 | Blog
SABCS's Social Media Ambassadors 2024
The SABCS 2024 (San Antonio Breast Cancer Symposium) will feature a group of Social Media…
Nov 12, 2024, 18:55 | Insight
Jayant Gadrey: Analysis of ongoing clinical trials of ADCs for patients with breast cancer brain metastases
Jayant Gadrey, Resident Physician at the Tufts Medical Center, shared a post on X by…
Nov 10, 2024, 16:37 | Insight
Incorporation of immunotherapy in the management of early-stage ER+ Breast Cancer
A recent paper by Guilherme Nader-Marta, Clinical Fellow at Dana-Farber Cancer Institute, was mentioned by…
Nov 9, 2024, 20:08 | Blog
Dr. Sara Tolaney Discusses ESMO24 Insights on TroFuse-010 Trial in Advanced Breast Cancer
Dana-Farber’s Breast Oncology Center shared the following on X: “Dr. Sara Tolaney discussed ESMO24 Insights…
Nov 5, 2024, 12:37 | Insight
Adding Inavolisib to Fulvestrant and Palbociclib in first line for patients with PIK3CA-Mutation
Komal Jhaveri, Associate Member at Memorial Sloan Kettering Cancer Center, shared a post on X…
Nov 2, 2024, 12:01 | Positive
Top 100 Xfluencers in Breast Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024
As Pink October has ended, it's time to reflect on Breast Cancer Awareness Month. OncoDaily…
Oct 29, 2024, 13:05 | Insight
Paolo Tarantino: My 100th scientific publication
Paolo Tarantino, Fellow at Dana-Farber Cancer Institute, shared a post on X: "It turns out…
Oct 25, 2024, 08:51 | Blog
Nirmit Kumar: Great overview of the history of Antibody Drug Conjugates by Raffaele Colombo et al.
Nirmit Kumar, Senior Global Medical Strategy Leader at AstraZeneca, shared a post by Paolo Tarantino…
Oct 24, 2024, 20:22 | Blog
Health Monitor Network - The latest insights for those facing HR+/HER2- metastatic breast cancer
Health Monitor Network shared on Linkedin: ''While October marks Breast Cancer Awareness Month, Health Monitor's…
Oct 23, 2024, 14:45 | Blog
Paolo Tarantino: How do we build a new generation of safer and more active ADCs for treating cancer
Paolo Tarantino and Raffaele Colombo shared posts on X, about recent paper published in Cancer…
Oct 22, 2024, 10:18 | Blog
An extensive overview on precision medicine by Paolo Tarantino and Sara Tolaney
Florez Lab shared a post on X: ''Dr. Paolo Tarantino and Dr. Sara Tolaney are…
Oct 20, 2024, 19:09 | Insight
Paolo Tarantino: Precision medicine for HR+ metastatic breast cancer: from hope to reality in little more than 5 years
Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute, shared on LinkedIn: “Precision medicine for HR+…
Oct 17, 2024, 17:01 | Blog
Sara Tolaney: A special event to celebrate Global Lobular Breast Cancer Awareness Day
Sara Tolaney shared a post on X: "October 15th is Global Lobular Breast Cancer Awareness Day!!!!!…
Oct 15, 2024, 11:55 | Insight
Overall survival with Pembrolizumab in early-stage TNBC - Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared a post on X: "Check out this Practice Update commentary from…
Oct 9, 2024, 14:00 | Blog
Oncoinfluencers to Follow on Social Media: Dr. Sara Tolaney
We are excited to introduce Dr. Sara Tolaney, a leading expert in breast oncology, as…
Oct 6, 2024, 07:42 | Positive
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 6
This week, we continue featuring 100 influential women in oncology, and here is the list…
Sep 20, 2024, 13:00 | Blog
The 1st webinar of the ’24-‘25 EMBRACE Metastatic Breast Cancer Forum Series - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute shared a post on X: ''Join Nancy Lin, and Sara Tolaney, via Zoom for…
Sep 18, 2024, 23:03 | Insight
Aleix Prat: Dual HER2 inhibition in Breast Cancer
Aleix Prat shared a post on X about a recent paper by Adrienne Waks et…
Sep 10, 2024, 10:45 | Blog
Sara Tolaney: Mark your calendars for PER’s School of Breast Oncology
Sara Tolaney shared a post on X: “Mark your calendars for PER’s School of Breast…
Sep 7, 2024, 19:36 | Insight
A year of treatment with an ADC has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute shared the following on LinkedIn: “A year of treatment with a medicine…
Sep 6, 2024, 11:25 | Insight
Paolo Tarantino: Interesting RWA of outcomes with chemotherapy in HR+/HER2- MBC
Paolo Tarantino shared a post by ESMO Open on X, adding: "Interesting real world analysis…
Sep 1, 2024, 15:26 | Insight
Guillermo Villacampa: Meta-analysis evaluating immunotherapy in early breast cancer
Recently, an article by Guillermo Villacampa et al. was published in JAMA Oncology. "Neoadjuvant Immune…
Jul 26, 2024, 00:18 | Blog
Sara Tolaney on novel therapies for young women with breast cancer at Young Women's Forum
Young Women's Forum shared on X: "Honored to have Sara Tolaney, Chief of Breast Oncology…
Jul 25, 2024, 08:58 | Insight
Marleen Kok: How do we get from one-size-fits-all to personalized treatment for TNBC
Marleen Kok, Breast Medical Oncologist at the Netherlands Cancer Institute, shared on X: "Today from…
Jul 14, 2024, 21:42 | Blog
Paolo Tarantino: Stellar Tumor Board session at the Harvard Medical School Breast Course
Paolo Tarantino shared a post on X: ''Stellar Tumor Board session at the Harvard Medical…
Jul 12, 2024, 20:47 | Societies
Stuart Schnitt on the future of breast pathology with the potential benefits of AI
Sara Tolaney shared on X: "Dr Stuart Schnitt does an outstanding job highlighting the future…
Jul 5, 2024, 05:41 | Blog
Abeid Athman: Joining ASCO had a huge role in shaping my career
Abeid Athman, Clinical Oncologist at Kenyatta University Hospital, shared on X: "It has been 5…
Jul 3, 2024, 22:59 | Blog
Aleix Prat: Our 2 articles published this week
Aleix Prat, Head of the Medical Oncology Department at Hospital Clínic Barcelona, shared on X:…
Jul 3, 2024, 10:44 | Blog
Abeid M. Athman Omar: The last four months have been very eventful for me
Abeid M. Athman Omar, Clinical Oncology Specialist at Kenyatta University, shared a post on LinkedIn: "The last…
Jul 3, 2024, 01:24 | Blog
Paolo Tarantino: ATEMPT would have not been possible without the vision of Sara Tolaney
Sara Tolaney shared a post by Paolo Tarantino on X: “Very lucky to get to…
Jul 2, 2024, 10:32 | Insight
Trastuzumab emtansine (T-DM1) is highly effective in preventing stage 1 HER2-positive breast cancer from recurring - MedEdge MEA
MedEdge MEA shared a post on LinkedIn:  . "A year of treatment with a medicine…
Jul 1, 2024, 15:23 | Insight
Paolo Tarantino: Final analysis of the ATEMPT phase 2 trial
Paolo Tarantino shared a post on X: “Can ADCs help prevent recurrence from breast cancer…
Jun 26, 2024, 03:41 | Insight
Paolo Tarantino: Opportunities to improve outcomes for early recurrent TNBC
Paolo Tarantino shared a post on X:         .  "Early recurrent TNBC (Triple-Negative…
Jun 22, 2024, 04:43 | Blog
Sara Tolaney: Please consider attending the School of Breast Oncology
Hope Rugo, Medical hematologist-oncologist at UCSF, shared a post by Sara Tolaney, on X: ''It is indeed.…
Jun 11, 2024, 15:21 | Blog
Abeid M. Athman Omar: Delighted to have received two awards at the ASCO24 meeting
Abeid M. Athman Omar, Clinical Oncology Specialist at Kenyatta University, shared a post on LinkedIn: ''I am…
May 31, 2024, 18:51 | Blog
Sameh Abdelmalak: Dr. Sara Tolaney and Dr. Hope Rugo discussing ASCO24 Noteworthy Abstracts in Breast Cancer
Sameh Abdelmalak, Director, Oncology, Educational Partnerships at VuMedi, made the following post on X: "Check…
May 22, 2024, 08:48 | Blog
SITC will host the free Summit on Immunomodulation of ADCs
Society for Immunotherapy of Cancer shared a post on X: “SITC will host the free Summit…
May 20, 2024, 13:16 | Career
Sara Tolaney is appointed as Alliance for Clinical Trials in Oncology Breast Committee Vice-Chair
Alliance for Clinical Trials in Oncology recently shared on X: "Congratulations to Sara Tolaney, MD,…
May 18, 2024, 10:02 | Societies
Matteo Lambertini: What a big honor to have Sara Tolaney at our ESMOYOC session
Matteo Lambertini, Medical Oncologist at San Martino, shared on X: . "What a big honor…
May 18, 2024, 09:54 | Societies
Paolo Tarantino: Why was IMpassion132 negative?
Daniel Stover, Medical Oncologist and Computational Biologist at Ohio State University Comprehensive Cancer Center, shared…
May 18, 2024, 08:12 | Blog
Paolo Tarantino: Sara Tolaney recapitulating 10+ years of de-escalation trials
Paolo Tarantino shared a post on X/Twitter: ''Terrific presentation by Sara Tolaney at ESMO Breast24, recapitulating…
May 18, 2024, 04:17 | Blog
Sara Tolaney: Interesting data from Mafalda Oliveira from SERENA-2 at ESMO Breast24
Sara Tolaney shared a post on X: ''Interesting data from Mafalda Oliveira from SERENA-2 demonstrating…
May 17, 2024, 11:41 | Insight
Sara Tolaney: Helpful discussion by Cristina Saura on how to think about adjuvant therapies in patients with gBRCAm
Sara Tolaney shared a post on X: “Very helpful discussion by Cristina Saura on how…
May 14, 2024, 16:00 | Blog
Dr. Sara Tolaney will be the invited discussant for three excellent Breast Cancer trials at ESMO Breast 24 - Dana Farber’s Breast Oncology Center
Dana Farber’s Breast Oncology Center shared a post on X: “Check out the ESMO Breast 24…
May 7, 2024, 11:51 | Positive
Sara Tolaney: HAPPY NURSES WEEK!
Sara Tolaney shared a post on X: "HAPPY NURSES WEEK! A special thank you to…
May 7, 2024, 03:53 | Blog
Aleix Prat: Dr. Tomás Pascual, will be co-presenting an educational talk alongside Sara Tolaney and Tatiana Prowell
Aleix Prat, Director of the Oncology Institute at Hospital Clínic Barcelona, shared a post on X:…
May 5, 2024, 06:21 | Blog
Sara Tolaney discussed the new breast cancer screening guidelines - Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared on their X/Twitter: ''Sara Tolaney discussed the new breast cancer…
May 1, 2024, 13:41 | Opinion
Sara Tolaney: Such an important question addressed in the Alliance A011502 study
Sara Tolaney shared a post by Erman Akkus, Medical Oncology Fellow at Ankara University, on X/Twitter: "Such…
Apr 22, 2024, 11:40 | Blog
Sara Tolaney: Very excited to have Aleix Prat as the Schlager Lecturer at the Harvard Breast Course in July!
Sara Tolaney shared a post by Aleix Prat, Co-Founder of Reveal Genomics, on X/Twitter, adding:…
Mar 24, 2024, 08:23 | Drugs
Paolo Tarantino: Adding palbociclib to fulvestrant did not improve PFS in the PACE randomized phase 2 trial
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on…
Feb 27, 2024, 15:28 | Blog
Dr. Sara Tolaney discusses Antibody Drug Conjugates - Dana-Farber’s Breast Oncology Center
Quoting Dana-Farber’s Breast Oncology Center on X/Twitter: "Dr. Sara Tolaney discusses Antibody Drug Conjugates in…
Feb 14, 2024, 13:13 | Blog
Chiara Corti: Thanks so much to Gianni Bonadonna Foundation and AIRC Foundation for cancer research for this opportunity
Chiara Corti, Research Fellow at Dana-Farber Cancer Institute, shared a post by Gianni Bonadonna Foundation…
Dec 17, 2023, 17:26 | Blog
25 Posts Not To Miss From SABCS 2023
The San Antonio Breast Cancer Symposium 2023 (SABCS 2023) took place in San Antonio, Texas…
Dec 8, 2023, 17:54 | Career
Dana-Farber News congratulates Sara Tolaney on receiving the Susan G. Komen 2023 Rising Star Researcher Award
Dana-Farber News /Dana Farber Cancer Institute/ shared on their X/Twitter account: "Congrats to Dana-Farber Cancer…
Nov 1, 2023, 18:54 | Societies
20 Posts Not To Miss From ESMO 2023 Congress
The Annual Congress of the European Society For Medical Oncology (ESMO) took place from October…
Oct 21, 2023, 21:40 | Positive
100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2023: Part 9
We continue OncoDaily’s ‘100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social…
Oct 13, 2023, 17:39 | Blog
Sara Tolaney: Consider applying to the Gilead Research Scholars program if you are a junior faculty member looking for funding for research in solid tumors!
Quoting Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, on…
Sep 15, 2023, 18:51 | Blog
Michail Ignatiadis: Join us tomorrow with ⁦Peter Fasching, Sara Tolaney and Stephen Johnston to discuss QoL in the phase 3 NATALEE trial of adjuvant ribociclib
Quoting Michail Ignatiadis, Director of Breast Medical Oncology Clinic & Program, Jules Bordet Institute, on…
Aug 25, 2023, 18:26 | Insight
Sara Tolaney: TROPICS-02 Overall Survival data now published in The Lancet!
Quoting Sara Tolaney, Chief of Division of Breast Oncology at Dana Farber Cancer Institute, on…
Aug 14, 2023, 17:39 | Insight
Check out the new review just published in Cancers MDPI on Tumor Mutational Burden in Breast Cancer - Dana-Farber’s Breast Oncology Center
Quoting from a recent tweet by Dana-Farber’s Breast Oncology Center: "Check out the new review…
All: 78 Posts: 1 - 100
Special Coverage